百利天恒(688506) - 2023 Q1 - 季度财报

Financial Performance - The company's operating revenue for Q1 2023 was ¥123,425,134.32, representing a year-on-year increase of 1.74%[5]. - The net profit attributable to shareholders was -¥166,829,778.91, with a basic and diluted earnings per share of -¥0.42[6][10]. - Total operating revenue for Q1 2023 was CNY 123,425,134.32, a 1.74% increase from CNY 121,313,587.38 in Q1 2022[21]. - Total operating costs for Q1 2023 were CNY 297,906,393.14, up 65.4% from CNY 180,350,834.09 in Q1 2022[21]. - Net loss for Q1 2023 was CNY 166,829,778.91, compared to a net loss of CNY 45,582,609.83 in Q1 2022[22]. - Basic and diluted earnings per share for Q1 2023 were both CNY -0.42, compared to CNY -0.13 in Q1 2022[23]. - Other comprehensive loss for Q1 2023 was CNY -3,309,126.89, compared to a gain of CNY 77,248.23 in Q1 2022[23]. Cash Flow - The net cash flow from operating activities was -¥187,898,141.80, primarily due to increased funding for R&D projects[10]. - Net cash flow from operating activities was -¥187.90 million, compared to -¥95.19 million in the previous year, indicating a decline of 97.5%[27]. - Total cash inflow from operating activities reached ¥141.84 million, up from ¥122.35 million, representing a growth of 15.5%[27]. - Cash outflow from operating activities increased to ¥329.74 million, compared to ¥217.54 million, marking a rise of 51.5%[27]. - Cash flow from investing activities was -¥29.20 million, worsening from -¥20.44 million year-over-year, reflecting a decline of 42.5%[28]. - Cash inflow from financing activities totaled ¥30.00 million, down from ¥85.94 million, a decrease of 65.1%[28]. - The net cash and cash equivalents decreased by ¥274.92 million, compared to a decrease of ¥86.18 million in the previous year, indicating a decline of 219.5%[28]. - The ending balance of cash and cash equivalents was ¥725.77 million, down from ¥1,000.69 million at the beginning of the period[28]. - The company reported a total operating cash inflow of ¥141.84 million, while total operating cash outflow was ¥329.74 million, leading to a significant negative cash flow[27]. Assets and Liabilities - Total assets at the end of the reporting period were ¥1,726,358,690.22, a decrease of 13.31% compared to the end of the previous year[6]. - Total assets decreased from CNY 1,991,433,372.18 in the previous year to CNY 1,726,358,690.22 in Q1 2023[19]. - Total liabilities decreased from CNY 1,057,454,165.04 in the previous year to CNY 962,518,388.88 in Q1 2023[19]. - The company's total equity attributable to shareholders decreased from CNY 933,979,207.14 in the previous year to CNY 763,840,301.34 in Q1 2023[19]. - Current liabilities totaled approximately $737.20 million, with no significant changes noted[32]. - Long-term borrowings were recorded at approximately $239.96 million, indicating stability in financing[32]. Research and Development - R&D investment totaled ¥158,935,991.07, an increase of 124.47% year-on-year, accounting for 128.77% of operating revenue, up by 70.41 percentage points[6][10]. - Research and development expenses increased significantly to CNY 158,935,991.07 in Q1 2023, up from CNY 70,804,618.86 in Q1 2022[22]. - The company is focusing on increasing its innovative drug pipeline, which has led to higher R&D expenditures[10]. Shareholder Information - The company had a total of 2,993 ordinary shareholders at the end of the reporting period[11]. - The largest shareholder, Zhu Yi, held 74.34% of the shares, amounting to 298,108,880 shares[12]. - There are no significant changes in the shareholder structure or major financing activities reported for the period[14]. Strategic Focus - The company is focusing on expanding its market presence and enhancing product development strategies[15]. - The company is committed to improving its financial health and operational efficiency in the upcoming quarters[15]. - The company has not disclosed any significant mergers or acquisitions during the reporting period[15].